Dbv technologies to participate in upcoming aaaai 2024 congress

Montrouge, france, february 20 2024 dbv technologies to participate in upcoming aaaai 2024 congress dbv technologies (euronext: dbv – isin: fr0010417345 –nasdaq: dbvt), a clinical-stage biopharmaceutical company focused on treatments for food allergies, today announced two presentations at the american academy of allergy, asthma, and immunology (aaaai) annual meeting, february 23-26 in washington, d.c. a poster presentation by david fleischer, m.d.
DBVT Ratings Summary
DBVT Quant Ranking